Clinical and molecular epidemiological features of critically ill patients with invasive group A Streptococcus infections: a Belgian multicenter case-series.
Community-acquired pneumonia
Critical care
Empyema
Group A streptococci
Influenza
Invasive
Necrotizing fasciitis
Streptococcus pyogenes
Toxic shock syndrome
Viral coinfection
Journal
Annals of intensive care
ISSN: 2110-5820
Titre abrégé: Ann Intensive Care
Pays: Germany
ID NLM: 101562873
Informations de publication
Date de publication:
29 Jan 2024
29 Jan 2024
Historique:
received:
09
09
2023
accepted:
14
01
2024
medline:
30
1
2024
pubmed:
30
1
2024
entrez:
29
1
2024
Statut:
epublish
Résumé
Recent alerts have highlighted an increase in group A streptococcal (GAS) infections since 2022 in Europe and the United States. Streptococcus pyogenes can cause limited skin or mucosal disease, but can also present as severe invasive disease necessitating critical care. We performed a multicenter retrospective study of patients with GAS infections recently admitted to Belgian intensive care units (ICUs) since January 2022. We describe patient characteristics and investigate the molecular epidemiology of the S. pyogenes strains involved. Between January 2022 and May 2023, a total of 86 cases (56 adults, 30 children) with GAS disease were admitted to critical care in the university hospitals of Leuven, Antwerp and Liège. We noted a strikingly high incidence of severe community-acquired pneumonia (sCAP) (45% of adults, 77% of children) complicated with empyema in 45% and 83% of adult and pediatric cases, respectively. Two-thirds of patients with S. pyogenes pneumonia had viral co-infection, with influenza (13 adults, 5 children) predominating. Other disease presentations included necrotizing fasciitis (23% of adults), other severe skin/soft tissue infections (16% of adults, 13% of children) and ear/nose/throat infections (13% of adults, 13% of children). Cardiogenic shock was frequent (36% of adults, 20% of children). Fifty-six patients (65%) had toxic shock syndrome. Organ support requirements were high and included invasive mechanical ventilation (77% of adults, 50% of children), renal replacement therapy (29% of adults, 3% of children) and extracorporeal membrane oxygenation (20% of adults, 7% of children). Mortality was 21% in adults and 3% in children. Genomic analysis of S. pyogenes strains from 55 out of 86 patients showed a predominance of emm1 strains (73%), with a replacement of the M1 The recent rise of severe GAS infections (2022-23) is associated with introduction of the M1
Sections du résumé
BACKGROUND
BACKGROUND
Recent alerts have highlighted an increase in group A streptococcal (GAS) infections since 2022 in Europe and the United States. Streptococcus pyogenes can cause limited skin or mucosal disease, but can also present as severe invasive disease necessitating critical care. We performed a multicenter retrospective study of patients with GAS infections recently admitted to Belgian intensive care units (ICUs) since January 2022. We describe patient characteristics and investigate the molecular epidemiology of the S. pyogenes strains involved.
RESULTS
RESULTS
Between January 2022 and May 2023, a total of 86 cases (56 adults, 30 children) with GAS disease were admitted to critical care in the university hospitals of Leuven, Antwerp and Liège. We noted a strikingly high incidence of severe community-acquired pneumonia (sCAP) (45% of adults, 77% of children) complicated with empyema in 45% and 83% of adult and pediatric cases, respectively. Two-thirds of patients with S. pyogenes pneumonia had viral co-infection, with influenza (13 adults, 5 children) predominating. Other disease presentations included necrotizing fasciitis (23% of adults), other severe skin/soft tissue infections (16% of adults, 13% of children) and ear/nose/throat infections (13% of adults, 13% of children). Cardiogenic shock was frequent (36% of adults, 20% of children). Fifty-six patients (65%) had toxic shock syndrome. Organ support requirements were high and included invasive mechanical ventilation (77% of adults, 50% of children), renal replacement therapy (29% of adults, 3% of children) and extracorporeal membrane oxygenation (20% of adults, 7% of children). Mortality was 21% in adults and 3% in children. Genomic analysis of S. pyogenes strains from 55 out of 86 patients showed a predominance of emm1 strains (73%), with a replacement of the M1
CONCLUSIONS
CONCLUSIONS
The recent rise of severe GAS infections (2022-23) is associated with introduction of the M1
Identifiants
pubmed: 38286885
doi: 10.1186/s13613-024-01249-7
pii: 10.1186/s13613-024-01249-7
doi:
Types de publication
Journal Article
Langues
eng
Pagination
19Informations de copyright
© 2024. The Author(s).
Références
Brouwer S, Rivera-Hernandez T, Curren BF, Harbison-Price N, De Oliveira DMP, Jespersen MG, et al. Pathogenesis, epidemiology and control of Group A Streptococcus infection. Nat Rev Microbiol. 2023;21(7):431–47.
doi: 10.1038/s41579-023-00865-7
pubmed: 36894668
pmcid: 9998027
Schmitz M, Roux X, Huttner B, Pugin J. Streptococcal toxic shock syndrome in the intensive care unit. Ann Intensive Care. 2018;8(1):88.
doi: 10.1186/s13613-018-0438-y
pubmed: 30225523
pmcid: 6141408
Kiska DL, Thiede B, Caracciolo J, Jordan M, Johnson D, Kaplan EL, et al. Invasive group A streptococcal infections in North Carolina: epidemiology, clinical features, and genetic and serotype analysis of causative organisms. J Infect Dis. 1997;176(4):992–1000.
doi: 10.1086/516540
pubmed: 9333158
van der Putten BCL, Vlaminckx BJM, de Gier B, Freudenburg-de Graaf W, van Sorge NM. Group A Streptococcal meningitis with the M1UK variant in the Netherlands. JAMA. 2023;329(20):1791–2.
doi: 10.1001/jama.2023.5927
pubmed: 37027150
pmcid: 10082416
de Gier B, Vlaminckx BJM, Woudt SHS, van Sorge NM, van Asten L. Associations between common respiratory viruses and invasive group A streptococcal infection: a time-series analysis. Influenza Other Respir Viruses. 2019;13(5):453–8.
doi: 10.1111/irv.12658
pubmed: 31237087
pmcid: 6692538
Zachariadou L, Stathi A, Tassios PT, Pangalis A, Legakis NJ, Papaparaskevas J, et al. Differences in the epidemiology between paediatric and adult invasive Streptococcus pyogenes infections. Epidemiol Infect. 2014;142(3):512–9.
doi: 10.1017/S0950268813001386
pubmed: 23746128
Zangarini L, Martiny D, Miendje Deyi VY, Hites M, Maillart E, Hainaut M, et al. Incidence and clinical and microbiological features of invasive and probable invasive streptococcal group A infections in children and adults in the Brussels-Capital Region, 2005–2020. Eur J Clin Microbiol Infect Dis. 2023;42(5):555–67.
doi: 10.1007/s10096-023-04568-y
pubmed: 36881216
pmcid: 9989989
Couture-Cossette A, Carignan A, Mercier A, Desruisseaux C, Valiquette L, Pepin J. Secular trends in incidence of invasive beta-hemolytic streptococci and efficacy of adjunctive therapy in Quebec, Canada, 1996–2016. PLoS ONE. 2018;13(10): e0206289.
doi: 10.1371/journal.pone.0206289
pubmed: 30352091
pmcid: 6198987
Nelson GE, Pondo T, Toews KA, Farley MM, Lindegren ML, Lynfield R, et al. Epidemiology of invasive Group A Streptococcal Infections in the United States, 2005–2012. Clin Infect Dis. 2016;63(4):478–86.
doi: 10.1093/cid/ciw248
pubmed: 27105747
Risk Assessment Group. Increasing number of invasive infections with group A streptococci (iGAS). https://www.sciensano.be/sites/default/files/rag_advice_igas_170123.pdf . Accessed 6 Sep 2023.
World Health Organization. Increased incidence of scarlet fever and invasive Group A Streptococcus infection - multi-country 2022. https://www.who.int/emergencies/disease-outbreak-news/item/2022-DON429 . Accessed on 6 Sep 2023.
Centers for Disease Control and Prevention. Increase in Pediatric Invasive Group A Streptococcal Infections 2022. https://emergency.cdc.gov/han/2022/han00484.asp . Accessed 6 Sep 2023.
Centers for Disease Control and Prevention. Streptococcus Disease, Invasive, Group A (GAS) (Streptococcus pyogenes) 1995 Case Definition. https://ndc.services.cdc.gov/case-definitions/streptococcus-disease-invasive-group-a-1995 . Accessed 6 Sep 2023.
Centers for Disease Control and Prevention. Streptococcal Toxic Shock Syndrome (STSS) (Streptococcus pyogenes) 2010 Case Definition. Available from: https://ndc.services.cdc.gov/case-definitions/streptococcal-toxic-shock-syndrome-2010 . Accessed 6 Sep 2023.
Taylor FB Jr, Toh CH, Hoots WK, et al. Scientific Subcommittee on Disseminated Intravascular Coagulation of the ISTH. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost. 2001;86(5):1327–30.
doi: 10.1055/s-0037-1616068
pubmed: 11816725
Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13(10):818–29.
doi: 10.1097/00003246-198510000-00009
pubmed: 3928249
Vincent JL, de Mendonca A, Cantraine F, et al. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on “sepsis-related problems” of the European Society of Intensive Care Medicine. Crit Care Med. 1998;26(11):1793–800.
doi: 10.1097/00003246-199811000-00016
pubmed: 9824069
Centers for Disease Control and Prevention. emm Typing Protocol [updated July 23, 2021]. https://www.cdc.gov/streplab/groupa-strep/resources.html#typing-protocol . Accessed 6 Sep 2023.
Steer AC, Law I, Matatolu L, Beall BW, Carapetis JR. Global emm type distribution of group A streptococci: systematic review and implications for vaccine development. Lancet Infect Dis. 2009;9(10):611–6.
doi: 10.1016/S1473-3099(09)70178-1
pubmed: 19778763
Lynskey NN, Jauneikaite E, Li HK, Zhi X, Turner CE, Mosavie M, et al. Emergence of dominant toxigenic M1T1 Streptococcus pyogenes clone during increased scarlet fever activity in England: a population-based molecular epidemiological study. Lancet Infect Dis. 2019;19(11):1209–18.
doi: 10.1016/S1473-3099(19)30446-3
pubmed: 31519541
pmcid: 6838661
Sumby P, Porcella SF, Madrigal AG, Barbian KD, Virtaneva K, Ricklefs SM, et al. Evolutionary origin and emergence of a highly successful clone of serotype M1 Group A Streptococcus involved multiple horizontal gene transfer events. J Infect Dis. 2005;192(5):771–82.
doi: 10.1086/432514
pubmed: 16088826
Bossuyt N, Vermeulen M, Denayer S, Barbezange C, De Schreye R, Moreels S, et al. Weekly bulletin acute respiratory infections - week 34. Sciensano 2023. https://www.sciensano.be/nl/gezondheidsonderwerpen/influenza/cijfers . Accessed 6 Sep 2023.
de Gier B, Marchal N, de Beer-Schuurman I, Te Wierik M, Hooiveld M, Group I-AS, et al. Increase in invasive group A streptococcal (Streptococcus pyogenes) infections (iGAS) in young children in the Netherlands, 2022. Euro Surveill. 2023;28(1):2200941.
pubmed: 36695447
pmcid: 9817208
Lassoued Y, Assad Z, Ouldali N, Caseris M, Mariani P, Birgy A, et al. Unexpected increase in invasive group A Streptococcal infections in children after respiratory viruses outbreak in France: a 15-year time-series analysis. Open Forum Infect Dis. 2023;10(5): ofad188.
doi: 10.1093/ofid/ofad188
pubmed: 37180594
pmcid: 10167988
Jain N, Lansiaux E, Reinis A. Group A streptococcal (GAS) infections amongst children in Europe: Taming the rising tide. New Microbes New Infect. 2023;51: 101071.
doi: 10.1016/j.nmni.2022.101071
pubmed: 36593885
Bagcchi S. Surge of invasive Group A streptococcus disease. Lancet Infect Dis. 2023;23(3):284.
doi: 10.1016/S1473-3099(23)00043-9
pubmed: 36669511
Tamayo E, Montes M, Vicente D, Perez-Trallero E. Streptococcus pyogenes pneumonia in adults: clinical presentation and molecular characterization of isolates 2006–2015. PLoS ONE. 2016;11(3): e0152640.
doi: 10.1371/journal.pone.0152640
pubmed: 27027618
pmcid: 4814053
Davies PJB, Russell CD, Morgan AR, Taori SK, Lindsay D, Ure R, et al. Increase of severe pulmonary infections in adults caused by M1(UK) Streptococcus pyogenes, Central Scotland, UK. Emerg Infect Dis. 2023;29(8):1638.
doi: 10.3201/eid2908.230569
pubmed: 37343545
pmcid: 10370863
Stockmann C, Ampofo K, Hersh AL, Blaschke AJ, Kendall BA, Korgenski K, et al. Evolving epidemiologic characteristics of invasive group a streptococcal disease in Utah, 2002–2010. Clin Infect Dis. 2012;55(4):479–87.
doi: 10.1093/cid/cis422
pubmed: 22534148
pmcid: 3520385
Boeddha NP, Atkins L, de Groot R, Driessen G, Hazelzet J, Zenz W, et al. Group A streptococcal disease in paediatric inpatients: a European perspective. Eur J Pediatr. 2023;182(2):697–706.
doi: 10.1007/s00431-022-04718-y
pubmed: 36449079
Walker MJ, Barnett TC, McArthur JD, Cole JN, Gillen CM, Henningham A, et al. Disease manifestations and pathogenic mechanisms of Group A Streptococcus. Clin Microbiol Rev. 2014;27(2):264–301.
doi: 10.1128/CMR.00101-13
pubmed: 24696436
pmcid: 3993104
Jain S, Self WH, Wunderink RG, Fakhran S, Balk R, Bramley AM, et al. Community-acquired pneumonia requiring hospitalization among U.S. adults. N Engl J Med. 2015;373(5):415–27.
doi: 10.1056/NEJMoa1500245
pubmed: 26172429
pmcid: 4728150
Jain S, Williams DJ, Arnold SR, Ampofo K, Bramley AM, Reed C, et al. Community-acquired pneumonia requiring hospitalization among U.S. children. N Engl J Med. 2015;372(9):835–45.
doi: 10.1056/NEJMoa1405870
pubmed: 25714161
pmcid: 4697461
Wilson PA, Varadhan H. Severe community-acquired pneumonia due to Streptococcus pyogenes in the Newcastle area. Commun Dis Intell. 2018;2020:44.
Liese JG, Schoen C, van der Linden M, Lehmann L, Goettler D, Keller S, et al. Changes in the incidence and bacterial aetiology of paediatric parapneumonic pleural effusions/empyema in Germany, 2010–2017: a nationwide surveillance study. Clin Microbiol Infect. 2019;25(7):857–64.
doi: 10.1016/j.cmi.2018.10.020
pubmed: 30395932
Herrera AL, Huber VC, Chaussee MS. The association between invasive group A Streptococcal diseases and viral respiratory tract infections. Front Microbiol. 2016;7:342.
doi: 10.3389/fmicb.2016.00342
pubmed: 27047460
pmcid: 4800185
Okamoto S, Kawabata S, Nakagawa I, Okuno Y, Goto T, Sano K, et al. Influenza A virus-infected hosts boost an invasive type of Streptococcus pyogenes infection in mice. J Virol. 2003;77(7):4104–12.
doi: 10.1128/JVI.77.7.4104-4112.2003
pubmed: 12634369
pmcid: 150641
Stevens DL, Kaplan EL. Streptococcal infections: clinical aspects, microbiology and molecular pathogenesis. ISBN 9780195099218 (2000).
Alcolea-Medina A, Snell LB, Alder C, Charalampous T, Williams TGS, Synnovis Microbiology Laboratory Group, et al. The ongoing Streptococcus pyogenes (Group A Streptococcus) outbreak in London, United Kingdom, in December 2022: a molecular epidemiology study. Clin Microbiol Infect. 2023;29(7):887–90.
doi: 10.1016/j.cmi.2023.03.001
pubmed: 36925107
pmcid: 10769882
Johannesen TB, Munkstrup C, Edslev SM, Baig S, Nielsen S, Funk T, et al. Increase in invasive group A streptococcal infections and emergence of novel, rapidly expanding sub-lineage of the virulent Streptococcus pyogenes M1 clone, Denmark, 2023. Euro Surveill. 2023;28(26):2300291.
doi: 10.2807/1560-7917.ES.2023.28.26.2300291
pubmed: 37382884
pmcid: 10311951
Ekelund K, Darenberg J, Norrby-Teglund A, Hoffmann S, Bang D, Skinhoj P, et al. Variations in emm type among group A streptococcal isolates causing invasive or noninvasive infections in a nationwide study. J Clin Microbiol. 2005;43(7):3101–9.
doi: 10.1128/JCM.43.7.3101-3109.2005
pubmed: 16000420
pmcid: 1169105
Cohen R, Ashman M, Taha MK, Varon E, Angoulvant F, Levy C, et al. Pediatric Infectious Disease Group (GPIP) position paper on the immune debt of the COVID-19 pandemic in childhood, how can we fill the immunity gap? Infect Dis Now. 2021;51(5):418–23.
doi: 10.1016/j.idnow.2021.05.004
pubmed: 33991720
pmcid: 8114587
National Reference Centre for invasive S. pneumonia. Report National Reference Centre S. pneumoniae 2022. https://www.sciensano.be/sites/default/files/report_nrc_srpn_2022_final_0.pdf . Accessed 6 Sep 2023.
Spellerberg B BC. Laboratory Diagnosis of Streptococcus pyogenes (group A streptococci) 2016. In: Streptococcus pyogenes : Basic Biology to Clinical Manifestations. University of Oklahoma Health Sciences Center. https://www.ncbi.nlm.nih.gov/books/NBK343617/ . Accessed 6 Sep 2023.
Dotel R, Bowen AC, Xie O, Gibney KB, Carapetis JR, Davis JS, Tong YC. Is it time for clinical trials of invasive group A and groups C and G Streptococcus infections? Clin Microbiol Infect. 2023;29(9):1205–7.
doi: 10.1016/j.cmi.2023.05.023
pubmed: 37244467
Klompas M, Baker MA, Rhee C, Baden LR. Strategic masking to protect patients from all respiratory viral infections. N Engl J Med. 2023;389:4–6.
doi: 10.1056/NEJMp2306223
pubmed: 37314330
Andrejko K, Whittles LK, Lewnard JA. Health-economic value of vaccination against group A Streptococcus in the United States. Clin Infect Dis. 2022;74(6):983–92.
doi: 10.1093/cid/ciab597
pubmed: 34192307